pyrazines has been researched along with Anemia, Hemolytic, Autoimmune in 6 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 5 (83.33) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
Authors | Studies |
---|---|
Yaqub, F | 1 |
Curtis, BR; Davies, SM; Filipovich, AH; Grimley, MS; Jodele, S; Jordan, MB; Khandelwal, P; Marsh, R | 1 |
Abdel-Azim, H; Kapoor, N; Mahadeo, K; Mehta, B; Tang, S; Zaw, R | 1 |
Cohen, C; Hosoba, S; Jaye, DL; Roback, JD; Waller, EK | 1 |
Beckwith, LG; Carson, KR; Mehta, J | 1 |
Danchaivijitr, P; Rapoport, AP; Yared, J | 1 |
1 review(s) available for pyrazines and Anemia, Hemolytic, Autoimmune
Article | Year |
---|---|
Successful treatment of severe immune hemolytic anemia after allogeneic stem cell transplantation with bortezomib: report of a case and review of literature.
Topics: Allografts; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Boronic Acids; Bortezomib; Erythropoiesis; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Count; Male; Middle Aged; Plasma Cells; Pyrazines; Recovery of Function | 2015 |
1 trial(s) available for pyrazines and Anemia, Hemolytic, Autoimmune
Article | Year |
---|---|
Bortezomib for refractory autoimmunity in pediatrics.
Topics: Adolescent; Adult; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Autoimmunity; Boronic Acids; Bortezomib; Child; Child, Preschool; Drug Administration Schedule; Female; Humans; Infant; Male; Neutropenia; Plasma Cells; Plasmapheresis; Proteasome Inhibitors; Pyrazines; Retrospective Studies; Rituximab; Thrombocytopenia | 2014 |
4 other study(ies) available for pyrazines and Anemia, Hemolytic, Autoimmune
Article | Year |
---|---|
2019 ASH Annual Meeting.
Topics: Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Pyrazines | 2020 |
Bortezomib for effective treatment of a child with refractory autoimmune hemolytic anemia post allogeneic hematopoietic stem cell transplant.
Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Prognosis; Pyrazines; Severe Combined Immunodeficiency; Transplantation, Homologous | 2014 |
Successful treatment of IgM-mediated autoimmune hemolytic anemia with bortezomib.
Topics: Aged; Anemia, Hemolytic, Autoimmune; Autoantibodies; Boronic Acids; Bortezomib; Female; Humans; Immunoglobulin M; Protease Inhibitors; Pyrazines | 2010 |
Successful treatment of IgG and complement-mediated autoimmune hemolytic anemia with bortezomib and low-dose cyclophosphamide.
Topics: Anemia, Hemolytic, Autoimmune; Boronic Acids; Bortezomib; Complement System Proteins; Cyclophosphamide; Female; Humans; Immunoglobulin G; Middle Aged; Pyrazines | 2011 |